Faeth Therapeutics (FTH) Other Operating Expenses (2020 - 2026)

Faeth Therapeutics (FTH) has reported Other Operating Expenses for 7 consecutive years, with $9.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 23050.0% year-over-year to $9.2 million; the trailing twelve-month figure through Jun 2026 stood at $162.3 million (up 2893.71% YoY), and the FY2025 full-year result was $11.0 million, down 44.02% from the prior year.
• Other Operating Expenses slipped to $9.2 million in Q2 2026 per FTH's latest filing, from $150.9 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $150.9 million in Q1 2026 and bottomed at -$191000.0 in Q2 2023.
• Historically, Other Operating Expenses has averaged $13.5 million across 5 years, with a median of $4.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Other Operating Expenses plunged 102.99% in 2023, then soared 754470.0% in 2026.
• Over 5 years, Other Operating Expenses stood at $7.3 million in 2022, then slumped by 100.08% to -$6000.0 in 2023, then jumped by 90766.67% to $5.4 million in 2024, then tumbled by 60.18% to $2.2 million in 2025, then jumped by 323.82% to $9.2 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $9.2 million, $150.9 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.